Document Detail

Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis.
MedLine Citation:
PMID:  3376987     Owner:  NLM     Status:  MEDLINE    
The authors administered repeated courses of intravenous immunoglobulin (IVIg) to nine patients at the onset of an exacerbation of generalized myasthenia gravis (MG). Anticholinesterase medication (nine patients) and corticosteroid dosage (six patients) had been kept constant for a 2-month period. Six patients received two courses, two patients received three courses, and one patient received five courses. Twenty of 23 courses resulted in satisfactory improvement beginning 4.3 +/- 1.2 days after start of IVIg and becoming maximal 8.2 +/- 2.0 days, with sustained improvement lasting 106.6 +/- 49.1 days. Vital capacity increased from an average of 1845.1 +/- 489 cc to 2894 +/- 762 cc (p less than 0.01) at peak effect. Four of nine patients had a decrease in strength before improvement. There was no significant change in acetylcholine receptor antibody titers before or after therapy. Side effects were minimal. Of the three patients who had nonsatisfactory course, two responded well to additional IVIg. IVIg can produce repeated beneficial effects in patients with MG and may be useful as an adjunct in the management of MG.
E L Arsura; A Bick; N G Brunner; D Grob
Related Documents :
3374767 - Tools to differentiate immunologic and non-immunologic myasthenia gravis in infancy.
14609487 - Idiopathic inflammatory myopathies: a treatment update.
25221187 - Or08-1insular activation during reward anticipation reflects duration of illness in abs...
21095627 - Incremental value and safety of oral ivabradine for heart rate reduction in computed to...
21281237 - Intermediate prognosis of 6q deletion in chronic lymphocytic leukemia.
14725217 - Role of manometry and ph-metry in patients with symptoms and signs of gastroesophageal ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of the medical sciences     Volume:  295     ISSN:  0002-9629     ISO Abbreviation:  Am. J. Med. Sci.     Publication Date:  1988 May 
Date Detail:
Created Date:  1988-07-07     Completed Date:  1988-07-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0370506     Medline TA:  Am J Med Sci     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  438-43     Citation Subset:  AIM; IM    
State University of New York Health Science Center, Brooklyn.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dose-Response Relationship, Immunologic
Drug Evaluation
Drug Therapy, Combination
Immunization, Passive* / adverse effects
Immunoglobulins / administration & dosage*
Infusions, Intravenous
Middle Aged
Myasthenia Gravis / therapy*
Neostigmine / administration & dosage
Prednisone / administration & dosage
Pyridostigmine Bromide / administration & dosage
Reg. No./Substance:
0/Immunoglobulins; 101-26-8/Pyridostigmine Bromide; 53-03-2/Prednisone; 59-99-4/Neostigmine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fluid phase coagulation events have minimal impact on plasma fibrin structure.
Next Document:  Effects of dietary electrolyte supplementation on gentamicin nephrotoxicity.